Background Advanced renal cell carcinoma is one of the most treatment-resistant
malignancies to conventional cytotoxic chemotherapy. The development of new targeted …

This article describes recent advances in the development and biological evaluation of small
molecule inhibitors for the serine/threonine kinase Akt (PKB). Akt plays a pivotal role in cell …

A specific ultra‐performance liquid chromatography tandem mass spectrometry method is
described for the simultaneous determination of bupropion, metroprolol, midazolam …

Basic transcription factor 3 (BTF3) acts as a transcription factor and modulator of apoptosis,
and is differentially expressed in colorectal cancer and glioblastomas. In the present study …

The RAS/RAF/MEK/ERK signaling pathway has been a major clinical focus in oncology
research in recent years. A clearer association of B-RAF mutations to cancers such as …

Erlotinib is a potent inhibitor of epidermal growth factor receptor tyrosine kinase and has
been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong …

BACKGROUND: The purpose of this study was to determine whether adding the anti-
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to …

Polymer microspheres are attracting wide attention in localized cancer therapy owing to the
excellent biocompatibility and drug loading capacity, controllable biodegradation speeds …

Purpose: The mechanism of sensitivity and resistance to epidermal growth factor receptor
(EGFR) inhibitors is incompletely understood, particularly in cancers other than non–small …

Pancreatic cancer is a lethal disease with a 5-year survival rate of 4%. The only opportunity
for improved survival continues to be complete surgical resection for those with localized …